BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34725726)

  • 21. Targeted Biopsy in Men High Risk for Prostate Cancer:
    Pepe P; Pennisi M
    Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraindividual Comparison of
    Kesch C; Vinsensia M; Radtke JP; Schlemmer HP; Heller M; Ellert E; Holland-Letz T; Duensing S; Grabe N; Afshar-Oromieh A; Wieczorek K; Schäfer M; Neels OC; Cardinale J; Kratochwil C; Hohenfellner M; Kopka K; Haberkorn U; Hadaschik BA; Giesel FL
    J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination of [
    Kim J; Lee S; Kim D; Kim HJ; Oh KT; Kim SJ; Choi YD; Giesel FL; Kopka K; Hoepping A; Lee M; Yun M
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1763-1772. PubMed ID: 38200396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer.
    Lopci E; Lughezzani G; Castello A; Colombo P; Casale P; Saita A; Buffi NM; Guazzoni G; Chiti A; Lazzeri M
    Clin Transl Oncol; 2021 Jan; 23(1):172-178. PubMed ID: 32447644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.
    Privé BM; Israël B; Schilham MGM; Muselaers CHJ; Zámecnik P; Mulders PFA; Witjes JA; Sedelaar M; Mehra N; Verzijlbergen F; Janssen MJR; Gotthardt M; Barentsz JO; van Oort IM; Nagarajah J
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):423-430. PubMed ID: 32999466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic performance of
    Zhang J; Shao S; Wu P; Liu D; Yang B; Han D; Li Y; Lin X; Song W; Cao M; Zhang J; Kang F; Qin W; Wang J
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):908-920. PubMed ID: 30635755
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.
    Qiu DX; Li J; Zhang JW; Chen MF; Gao XM; Tang YX; Zhang Y; Yi XP; Yin HL; Gan Y; Wang GL; Zu XB; Hu S; Cai Y
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2821-2832. PubMed ID: 34860277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer.
    Bodar YJL; Veerman H; Meijer D; de Bie K; van Leeuwen PJ; Donswijk ML; van Moorselaar RJA; Hendrikse NH; Boellaard R; Oprea-Lager DE; Vis AN
    BJU Int; 2022 Jun; 129(6):768-776. PubMed ID: 35166426
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Zhang LL; Li WC; Xu Z; Jiang N; Zang SM; Xu LW; Huang WB; Wang F; Sun HB
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):483-492. PubMed ID: 32734457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical and histopathological validation of
    Heetman JG; Hermsen R; Exterkate L; Küsters-Vandevelde HVN; Brouwer LJM; Somford DM; van den Bergh RCN; van Basten JA
    Prostate; 2023 Oct; 83(14):1332-1341. PubMed ID: 37455399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI.
    Laudicella R; Rüschoff JH; Ferraro DA; Brada MD; Hausmann D; Mebert I; Maurer A; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3917-3928. PubMed ID: 35435496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.